Abstract of the Disclosure

[0185] The invention concerns methods for improvement of lung function by administering non-peptide small molecule inhibitors of TGF- β specifically binding to the type I TGF- β receptor (TGF β -R1). Preferably, the inhibitors are quinazoline derivatives.

SV 445520 v1 7/23/03 12:13 PM (39739.0028)